Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma

Diagnostic Molecular Pathology

Volumn 18, Issue 1, 2009, Pages 30-33

  Shah, Sejal S ^a   Wang, Yan ^b   Tull, Jamie ^a   Zhang, Shengle ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast carcinoma; FISH; HER2; Immunohistochemistry; Polysomy 17

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CALCULATION; CELL NUCLEUS; CHROMOSOME 17; COMPARATIVE STUDY; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA; FEMALE; GENE DOSAGE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POLYPLOIDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; POLYPLOIDY; RECEPTOR, ERBB-2;

EID: 62449197958     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31817c1af8     Document Type: Article

References (16)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science. 1987;235:177-182.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
3. Carr JA, Havstad S, Zarbo RJ, et al. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000;135: 1469-1474.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-792.
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20: 719-726.
6. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
7. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29:1221-1227.
8. Bose S, Mohammed M, Shintaku P, et al. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J. 2001;7:337-344.
9. Farabegoli F, Ceccarelli C, Santini D, et al. c-erbB-2 overexpressiorv in amplified and non-amplified breast carcinoma samples. Int J Cancer (Pred Oncol). 1999;84:273-277.
10. Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 2003;5: 155-159.
11. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and Path Vysion FISH assay. Am J Clin Pathol. 2004; 121:70-77.
12. Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer. 2007;43:2339-2344.
13. Lago LD, Durbecq V, Desmedt C, et al. Correlation for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 2006;5: 2572-2579.
14. Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008;61:89-94.
15. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and Gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
16. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279-286.